ijms-logo

Journal Browser

Journal Browser

Head and Neck Cancer: From Molecular Diagnosis to Targeted Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1998

Special Issue Editor


E-Mail Website
Guest Editor
Department of Microscopic Morphology/Histology, Angiogenesis Research Center, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
Interests: head and neck cancer; otorhinolaryngology; molecular diagnosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Head and neck squamous cell carcinoma (HNSCC) is a pressing concern due to its rising incidence in Europe and worldwide. HNSCCs are aggressive tumors often diagnosed at an advanced stage, posing significant challenges for effective treatment. The current therapeutic options are notably limited and fall short in providing comprehensive solutions.

In recent years, molecular approaches have shown promise for applications in diagnosing and providing implicit therapy for HNSCC. Notably, molecular methods have aimed to classify these tumors based on their anatomical locations, offering potential insights into tailoring treatment strategies.

We invite you, dear colleagues, to contribute to this Special Issue by submitting original research papers, insightful reviews, or concise communications focused on head and neck cancer pathology, diagnosis, and treatment. Manuscripts proposing novel, targeted therapeutic approaches grounded in molecular analyses will be the main focus of the Special Issue.

We firmly believe that, with your invaluable contributions, we can develop a molecular classification for head and neck tumors, a critical element currently absent in the field. Such a classification holds the promise of paving the way for personalized therapies. Furthermore, we hope to identify new molecular therapeutic targets that can be used to stratify these pathologically apparently remarkably uniform tumors.

This Special Issue is being coordinated by Prof. Dr. Marius L. Raica in conjunction with our Guest Editor's assistant Dr. Cristina-Stefania Dumitru [email protected] (Department of Microscopic Morphology/Histology, Angiogenesis Research Center, “Victor Babes” University of Medicine and Pharmacy, Sq. Eftimie Murgu no. 2, 300041 Timisoara, Timis, Romania).

Prof. Dr. Marius L. Raica
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • head and neck cancer
  • targeted therapy
  • tumor genetics
  • biomarkers
  • combination therapy
  • resistance to therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 4621 KiB  
Article
Effect of Mifepristone on Migration and Proliferation of Oral Cancer Cells
by Anem Iftikhar, Simon Shepherd, Sarah Jones and Ian Ellis
Int. J. Mol. Sci. 2024, 25(16), 8777; https://doi.org/10.3390/ijms25168777 - 12 Aug 2024
Viewed by 839
Abstract
Glucocorticoid receptor (GR) overexpression has been linked to increased tumour aggressiveness and treatment resistance. GR antagonists have been shown to enhance treatment effectiveness. Emerging research has investigated mifepristone, a GR antagonist, as an anticancer agent with limited research in the context of oral [...] Read more.
Glucocorticoid receptor (GR) overexpression has been linked to increased tumour aggressiveness and treatment resistance. GR antagonists have been shown to enhance treatment effectiveness. Emerging research has investigated mifepristone, a GR antagonist, as an anticancer agent with limited research in the context of oral cancer. This study investigated the effect of mifepristone at micromolar (µM) concentrations of 1, 5, 10 and 20 on the proliferation and migration of oral cancer cells, at 24 and 48 h. Scratch and scatter assays were utilised to assess cell migration, MTT assays were used to measure cell proliferation, Western blotting was used to investigate the expression of GR and the activation of underlying Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) and mitogen-activated protein kinase (MAPK) signalling pathways, and immunofluorescence (IF) was used to determine the localisation of proteins in HaCaT (immortalised human skin keratinocytes), TYS (oral adeno squamous cell carcinoma), and SAS-H1 cells (squamous cell carcinoma of human tongue). Mifepristone resulted in a dose-dependent reduction in the proliferation of HaCaT, TYS, and SAS-H1 cells. Mifepristone at a concentration of 20 µM effectively reduced collective migration and scattering of oral cancer cells, consistent with the suppression of the PI3K-Akt and MAPK signalling pathways, and reduced expression of N-Cadherin. An elongated cell morphology was, however, observed, which may be linked to the localisation pattern of E-Cadherin in response to mifepristone. Overall, this study found that a high concentration of mifepristone was effective in the suppression of migration and proliferation of oral cancer cells via the inhibition of PI3K-Akt and MAPK signalling pathways. Further investigation is needed to define its impact on epithelial–mesenchymal transition (EMT) markers. Full article
(This article belongs to the Special Issue Head and Neck Cancer: From Molecular Diagnosis to Targeted Therapy)
Show Figures

Figure 1

16 pages, 3629 KiB  
Article
NMR-Based Metabolomics of Blood Serum in Predicting Response to Induction Chemotherapy in Head and Neck Cancer—A Preliminary Approach
by Łukasz Boguszewicz, Agata Bieleń, Jarosław Dawid Jarczewski, Mateusz Ciszek, Agnieszka Skorupa, Jolanta Mrochem-Kwarciak, Krzysztof Składowski and Maria Sokół
Int. J. Mol. Sci. 2024, 25(14), 7555; https://doi.org/10.3390/ijms25147555 - 10 Jul 2024
Viewed by 898
Abstract
The role of induction chemotherapy (iCHT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) is still to be established due to high toxicity and variable response rates. The aim of this retrospective study is to use NMR-based serum metabolomics to predict [...] Read more.
The role of induction chemotherapy (iCHT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) is still to be established due to high toxicity and variable response rates. The aim of this retrospective study is to use NMR-based serum metabolomics to predict the response rates to iCHT from the pretreatment samples. The studied group consisted of 46 LA-HNSCC patients treated with iCHT. The response to the treatment was evaluated by the clinical, fiberoptic, and radiological examinations made before and after iCHT. The proton nuclear magnetic resonance (1H NMR) serum spectra of the samples collected before iCHT were acquired with a 400 MHz spectrometer and were analyzed using multivariate and univariate statistical methods. A significant multivariate model was obtained only for the male patients. The treatment-responsive men with >75% primary tumor regression after iCHT showed pretreatment elevated levels of isoleucine, alanine, glycine, tyrosine, N-acetylcysteine, and the lipid compounds, as well as decreased levels of acetate, glutamate, formate, and ketone bodies compared to those who did not respond (regression of the primary tumor <75%). The results indicate that the nutritional status, capacity of the immune system, and the efficiency of metabolism related to protein synthesis may be prognostic factors for the response to induction chemotherapy in male HNSCC patients. However, larger studies are required that would validate the findings and could contribute to the development of more personalized treatment protocols for HNSCC patients. Full article
(This article belongs to the Special Issue Head and Neck Cancer: From Molecular Diagnosis to Targeted Therapy)
Show Figures

Figure 1

Back to TopTop